With the Alzheimer's Association International Conference underway in Washington, DC, there's been a big focus on the late-stage pipeline. But scientists at NYU Langone Medical Center were focused on new animal data that they say supports work on a new group of antibodies that can tackle two of the chief culprits behind the brain-damaging disease.
A global team of scientists working with Johns Hopkins' Jordan Green has developed a new nonviral gene therapy for brain cancer, successfully testing it in the lab in cell lines as well as rat models for the disease. Read more >>
Universities regularly woo top scientists from rival institutions, recruiting not only high-profile individuals but their lab teams as well in the hope of bagging promising science and the millions in federal funding that go along with it. But in a rare confrontation, UC San Diego has sued USC and research scientist Paul Aisen for an alleged conspiracy to purloin data and investigators involved in prominent Alzheimer's research work. Read more >>
POPULAR COMMENT THREADS
Yale scientists successfully tried out Pfizer's rheumatoid arthritis drug Xeljanz (tofacitinib) on a small group of people suffering from severe, treatment-resistant eczema, highlighting its added promise after the drug also demonstrated its potential in fighting two other skin conditions.
Professor Nicholas Tonks and colleagues at Cold Spring Harbor Laboratory say that they've seen a promising response to PTP1B inhibitors in mouse models of Rett syndrome, an X-linked disorder that generally kills boys early in life while severely disrupting the lives of girls.
Researchers at the University of Southampton have developed a small molecule which they refer to as "Compound 14" that deceives cells into thinking they have run out of energy--spurring on glucose uptake and increasing metabolism.
CRISPR/Cas9 tech and gene editing has emerged as a hot field in biotech, spurring a full slate of startups. Now one of the pioneers in the field has supervised a project that points to a more efficient use of technology in editing T cells.
A research team at Massachusetts General developed a gene therapy to deliver a protein that demonstrated signs of successfully reining in recurrent ovarian cancer in a mouse model for the disease.
From Our Sister Sites
Israeli startup Eximo Medical has gained a tiny $1.6 million Series A financing to get into the clinic with its disposable catheter that combines an ablation laser with a surgical blade. The device technology, known as Cathi, is expected to improve accuracy and offer superior precision in navigating vessel blockage regardless of the type or size of lesion.
Ariad Pharmaceuticals has inked a deal with PDL BioPharma, trading a long-term royalty on its only marketed drug in exchange for money to develop another.